Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - phenobarbital, quantity: 3 mg/ml - oral liquid, solution - excipient ingredients: purified water; ethanol; glycerol; sorbitol; flavour - indications as at 16 january 2002: treatment of epilepsy.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: water for injections - sodium valproate juno is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - phenobarbital sodium - solution for injection - 15mg/1ml

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 32.4 mg - - sedative - anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance – phenobarbital is a schedule iv drug. dependence – barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intox

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

state of florida doh central pharmacy - phenytoin sodium (unii: 4182431bjh) (phenytoin - unii:6158tkw0c5) - phenytoin sodium 100 mg - extended phenytoin sodium capsules, usp are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration and clinical pharmacology sections). phenytoin is contraindicated in those patients who are hypersensitive to phenytoin or other hydantoins.

Malaysia - Tiếng Anh - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

idaman pharma sdn. bhd. - phenobarbital sodium -

Kenya - Tiếng Anh - Pharmacy and Poisons Board

united pharma (k) limited united pharma (k) limited - phenobarbital sodium bp - injection - 60mg in 1ml - opium

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

cardinal health - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 0.2 g in 5 ml - neut (4% sodium bicarbonate additive solution) is indicated for use as an additive to raise the ph of acid solutions administered intravenously to reduce the incidence of chemical phlebitis and patient discomfort due to vein irritation at or near the site of infusion. not for use as a systemic alkalizer. none known.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

meda pharmaceuticals - butabarbital sodium (unii: 9wtd50i918) (butabarbital - unii:p0078o25a9) - butabarbital sodium 30 mg - butisol sodium® (butabarbital sodium tablets, usp and butabarbital sodium oral solution, usp) is indicated for use as a sedative or hypnotic. since barbiturates appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks, use of butisol sodium® in treating insomnia should be limited to this time (see clinical pharmacology above). barbiturates are contraindicated in patients with known barbiturate sensitivity. barbiturates are also contraindicated in patients with a history of manifest or latent porphyria. controlled substance: schedule iii. abuse and dependence: abuse and addiction are separate and distinct from physical dependence and tolerance. abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug and/or ad

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - phenytoin sodium (unii: 4182431bjh) (phenytoin - unii:6158tkw0c5) - phenytoin sodium 100 mg - extended phenytoin sodium capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. extended phenytoin sodium capsules are contraindicated in patients with: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as extended phenytoin sodium capsules, during pregnancy. physicians are advised to recommend that pregnant patients taking extended phenytoin sodium capsules enroll in the north american antiepileptic drug (naaed) pregnancy registry. this can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. information on the registry can also be found at the website http://www.aedpregnancyregistry.org/ risk summary in humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse